Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?

• Main Authors: Mau, Ern Poh, Chai, Chee Shee, Chong, Kin Liam, Go, Fuang Ho, Yong, Kek Pang, Harissa, Husainy Hasbullah, Lye, Mun Tho, Ibtisam, Muhamad Nor, Kean, Fatt Ho, Muthukkumaran, Thiagarajan, Azlina, Samsudin, Azza, Omar, Choo, Khoon Ong, Sing, Yang Soon, Sin, Nee Tan, Soon, Hin How
• Format: Article
• Language: English
• Published: AME Publishing Company 2024
• Subjects: R Medicine (General); RC0254 Neoplasms. Tumors. Oncology (including Cancer); RZ Other systems of medicine
• Online Access: http://ir.unimas.my/id/eprint/44420/3/Does%20dose.pdf; http://ir.unimas.my/id/eprint/44420/; https://tlcr.amegroups.org/article/view/83673/html; https://dx.doi.org/10.21037/tlcr-23-691

Background: Afatinib can be started at a dose lower than the recommended starting dose of 40 mg/day for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), however treatment outcomes in real-world clinical practice remains unclear. Methods: This retro...